Biotech & Pharma Companies
Portfolio Strategy for Biotech and Pharma Companies
MIM helps biotech and pharma companies manage intellectual property across core programs, non-core assets, shelved opportunities, and complex portfolio transitions.
Life-sciences portfolios rarely stay static. Programs shift. Indications change. Internal priorities move. Valuable assets can become non-core long before they lose external relevance. MIM is designed to help companies manage that reality — not just by prosecuting patents, but by evaluating portfolio quality, identifying underrecognized value, and preparing assets for the right downstream path.
What We Help Clients Do
Refine patent strategy for complex scientific portfolios
Assess non-core, deprioritized, or shelved assets for external value
Improve cost-to-value discipline across estate management decisions
Strengthen claim coverage and identify opportunities for additional filings
Prepare assets for licensing, partnerships, spinout evaluation, or other value-realization pathways
AI-Enabled Portfolio Assessment
MIM combines partner-level legal and strategic judgment with AI-assisted portfolio review to help identify overlooked value across biotech and pharma estates. That can include triaging non-core assets, surfacing opportunities for additional filings or claim strengthening, and ranking assets for further internal focus or external pathway review.
Why This Matters
A biotech or pharma portfolio cannot be managed effectively as a series of isolated filing decisions. It has to be governed as a strategic asset base shaped by science, timelines, internal resource constraints, partnering logic, and transaction readiness. MIM is built to help clients make those decisions more deliberately.
When Adjacent Capabilities Are Needed
Some matters require more than legal support alone. Where a client’s needs extend into scientific development planning, broader commercialization support, or evaluation of venture-oriented pathways for selected assets, separate non-legal capabilities may be available through the broader Miletus ecosystem where appropriate. Those capabilities remain distinct from MIM’s legal engagement and do not alter MIM’s independence as counsel.
How We Structure Engagements
Biotech and pharma engagements may be ongoing, fixed-term, portfolio-specific, or tied to a particular transition point — such as a non-core asset review, transaction-readiness effort, claim-set strengthening initiative, or broader portfolio reset. The structure depends on the portfolio and the decision context, not on a single preferred billing format.